Cancer and Tumor Biomarker-Based Assay Market Size, Share and Growth Outlook, 2026

Cancer and Tumor Biomarker-Based Assay Market Snapshot: Market Size, CAGR, and Growth Outlook (2021 to 2034)

The global Cancer and Tumor Biomarker-Based Assay Market size is forecast to increase from $13.21 Billion in 2026 to $32.94 Billion in 2034 at a CAGR of 12.1% between 2026 and 2034.

The Cancer and Tumor Biomarker-Based Assay market report provides detailed analysis and outlook of Cancer and Tumor Biomarker-Based Assay segments including By Biomarker (Protein Biomarkers, Genetic Biomarkers, Epigenetic Biomarkers, Metabolic Biomarkers), By Assay Technology (Immunoassays, Polymerase Chain Reaction, Next-Generation Sequencing, Immunohistochemistry, Mass Spectrometry & Flow Cytometry, Liquid Biopsy Assays ), By Indication (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical and Ovarian Cancer, Hematological Malignancies), By Clinical Application (Screening and Early Detection, Diagnostic Confirmation & Staging, Prognostic and Risk Assessment, Companion Diagnostics, Treatment Monitoring and Recurrence Surveillance), By End-User (Hospital and Reference Laboratories, Specialty Oncology and Cancer Clinics, Pharmaceutical and Biotechnology Companies, Academic and Clinical Research Institutes) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.

Cancer and Tumor Biomarker-Based Assay Industry Overview

Biomarker-Driven Diagnostics Advancing Precision Oncology

The cancer and tumor biomarker-based assay industry is experiencing significant transformation as healthcare systems increasingly adopt non-invasive diagnostic technologies that leverage molecular and protein biomarkers for early disease detection and monitoring. A major development in this field comes from Roche Diagnostics with the international launch of its comprehensive Liver Disease Panel. The platform combines blood-based biomarker analysis using the Elecsys PRO-C3 assay with the CE-marked LiverPRO digital algorithm to support the management of chronic liver disease and monitor progression toward liver cancer. By utilizing routine laboratory profiles and advanced algorithmic interpretation, the system calculates precise liver fibrosis risk parameters without requiring invasive tissue biopsy procedures. This shift toward blood-based biomarker assays reflects the growing demand for patient-friendly diagnostic solutions capable of supporting earlier intervention, disease stratification, and continuous monitoring within oncology care pathways.

Companion Diagnostic Assays Supporting Targeted Cancer Therapies

The increasing adoption of precision medicine is driving demand for highly specialized biomarker-based assays that identify patients most likely to benefit from targeted therapies. Merck & Co. has expanded its clinical diagnostic framework supporting the development of sacituzumab tirumotecan (sac-TMT), an investigational antibody-drug conjugate. Working with development partners, the company is standardizing quantitative immunohistochemistry (IHC) biomarker assays to evaluate human trophoblast cell-surface antigen 2 (TROP2) expression levels among participants enrolled across 17 global Phase 3 oncology studies. These assays provide critical patient selection tools by measuring tumor-specific biomarker expression and helping clinicians align therapeutic strategies with underlying molecular characteristics. As oncology drug development increasingly relies on companion diagnostics, biomarker-based assay technologies are becoming essential components of clinical trial design, treatment selection, and personalized cancer management.

Real-Time Biomarker Monitoring Reshaping Clinical Research

Regulatory innovation is further accelerating growth within the cancer and tumor biomarker-based assay industry. The U.S. Food and Drug Administration introduced a groundbreaking framework designed to support Real-Time Clinical Trials (RTCT), shifting away from conventional delayed endpoint assessments toward continuous data collection and analysis. Developed through pilot collaborations with AstraZeneca and Amgen, the initiative enables direct streaming of trial data from clinical sites to regulatory authorities. Central to this model is the real-time monitoring of genetic biomarkers and molecular signaling pathways that provide early indicators of treatment response and safety outcomes. By leveraging continuous biomarker telemetry, clinical researchers can identify therapeutic trends more rapidly, accelerate safety evaluations, and optimize development pathways for targeted anti-cancer therapies. This evolution is positioning biomarker-based assays as foundational tools in next-generation oncology research, regulatory science, and precision medicine ecosystems.

Cancer and Tumor Biomarker-Based Assay Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities

The global Cancer and Tumor Biomarker-Based Assay market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Siemens Healthineers AG, PerkinElmer, Inc. (Revvity), bioMérieux SA. The Cancer and Tumor Biomarker-Based Assay market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Cancer and Tumor Biomarker-Based Assay industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-

• Growth Cancer and Tumor Biomarker-Based Assay Market size outlook across 3 scenarios- High growth, reference, and Low growth cases

• Market Trends, Drivers, Potential Opportunities, and Challenges faced by Cancer and Tumor Biomarker-Based Assay companies

• Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry

• Detailed SWOT Analysis of global and regional Cancer and Tumor Biomarker-Based Assay markets

• Competitive analysis including business description, product analysis, and financial profiles

• Key country specific analysis detailing key factors shaping the short-term and long-term outlook

• Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements

Cancer and Tumor Biomarker-Based Assay Market Competitive Benchmarking and Company Analysis

Leading companies in Cancer and Tumor Biomarker-Based Assay industry include- F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Illumina, Inc., Abbott Laboratories, Agilent Technologies, Inc., QIAGEN N.V., Bio-Rad Laboratories, Inc., Siemens Healthineers AG, PerkinElmer, Inc. (Revvity), bioMérieux SA. The Cancer and Tumor Biomarker-Based Assay market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.

What to expect in US Cancer and Tumor Biomarker-Based Assay Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034

The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Cancer and Tumor Biomarker-Based Assay market remains one of the strongest-performing segments in the country.
The US Cancer and Tumor Biomarker-Based Assay Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Cancer and Tumor Biomarker-Based Assay market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Cancer and Tumor Biomarker-Based Assay industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.

Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Cancer and Tumor Biomarker-Based Assay markets

Canada's strong Cancer and Tumor Biomarker-Based Assay sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Cancer and Tumor Biomarker-Based Assay market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.

Germany Cancer and Tumor Biomarker-Based Assay Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.

Germany continues to remain the largest Cancer and Tumor Biomarker-Based Assay market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Cancer and Tumor Biomarker-Based Assay population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Cancer and Tumor Biomarker-Based Assay industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Cancer and Tumor Biomarker-Based Assay market outlook.

France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Cancer and Tumor Biomarker-Based Assay sales through 2034

France Cancer and Tumor Biomarker-Based Assay companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.

UK Cancer and Tumor Biomarker-Based Assay Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain

Small high-need consumer segments remain key priority of Cancer and Tumor Biomarker-Based Assay distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or £280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was £49 billion (14.1%) and voluntary health insurance was £9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.

China Cancer and Tumor Biomarker-Based Assay Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years

China Cancer and Tumor Biomarker-Based Assay market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Cancer and Tumor Biomarker-Based Assay industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Cancer and Tumor Biomarker-Based Assay industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.

India Cancer and Tumor Biomarker-Based Assay Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India

Indian Cancer and Tumor Biomarker-Based Assay market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.

Brazil Cancer and Tumor Biomarker-Based Assay market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities

Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.

Middle East and Africa Cancer and Tumor Biomarker-Based Assay Industry Trends and Perspectives to 2034

According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.

Cancer and Tumor Biomarker-Based Assay Market Segmentation

By Biomarker
Protein Biomarkers
Genetic Biomarkers
Epigenetic Biomarkers
Metabolic Biomarkers
By Assay Technology
Immunoassays
Polymerase Chain Reaction
Next-Generation Sequencing
Immunohistochemistry
Mass Spectrometry & Flow Cytometry
Liquid Biopsy Assays
By Indication
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Cervical and Ovarian Cancer
Hematological Malignancies
By Clinical Application
Screening and Early Detection
Diagnostic Confirmation & Staging
Prognostic and Risk Assessment
Companion Diagnostics
Treatment Monitoring and Recurrence Surveillance
By End-User
Hospital and Reference Laboratories
Specialty Oncology and Cancer Clinics
Pharmaceutical and Biotechnology Companies
Academic and Clinical Research Institutes

Top Companies in Cancer and Tumor Biomarker-Based Assay Industry

F. Hoffmann-La Roche Ltd
Thermo Fisher Scientific Inc.
Illumina, Inc.
Abbott Laboratories
Agilent Technologies, Inc.
QIAGEN N.V.
Bio-Rad Laboratories, Inc.
Siemens Healthineers AG
PerkinElmer, Inc. (Revvity)
bioMérieux SA

Countries Included

• North America- US, Canada, Mexico

• Europe- Germany, France, UK, Spain, Italy, Nordics, Others

• Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others

• Latin America- Brazil, Argentina, Others

• Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa

Latest Market Updates In Healthcare

Support this report with fresh, same-industry updates that strengthen topical depth and internal linking.

Market Update

Rise of Functional and Clinical-Grade Skincare

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Biotech and Fermented Ingredient Integration to gain rapid penetration

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025

Market Update

Low MOQ, High-Mix Production Models for Indie & DTC Brands

The rising geopolitical and tariff-related uncertainties, in particular, amidst United States’ renewed protectionist trade stance continues to driv...

June 2025